Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New method enables researchers to make human SARS antibodies quickly

12.07.2004


Human antibodies that thwart the SARS virus in mice can be mass-produced quickly using a new laboratory technique developed by an international research team collaborating with the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The new technique could become an important tool for developing a cocktail of SARS-specific antibodies that might help protect people recently exposed to the SARS virus or at high risk of exposure. The technique could also make possible the development of a similar approach to prevent or treat other illnesses, such as HIV/AIDS and hepatitis C.



The report describing these findings appears in the July 11, 2004, online issue of Nature Medicine.

"While much has been accomplished in our quest for a vaccine against SARS, a vaccine may provide little benefit to someone already infected," says Anthony S. Fauci, M.D., director of NIAID. "Human SARS antibodies could offer a double benefit: they could be used as a potent frontline defense for health care workers and others at high risk of exposure and as an effective treatment for those individuals newly exposed to the virus." Currently, there is no specific effective treatment for SARS.


SARS is caused by a coronavirus, a family of viruses named for their spiky, crown-like appearance. Highly contagious, SARS typically begins with flu-like symptoms, such as fever, headache and muscle aches, and generally progresses to pneumonia. In the 2003 global outbreak, more than 8,000 people were infected with SARS, 9 percent of whom died. In April 2004, a small outbreak in China is suspected to have begun as a result of negligent laboratory practices.

In the current study, Elisabetta Traggiai, Ph.D., and Antonio Lanzavecchia, M.D., from the Institute for Research in Biomedicine, Bellinzona, Switzerland, together with an international research team, generated human antibodies against SARS far more quickly and efficiently than with current methods. Moreover, collaborators Kanta Subbarao, M.D., and Brian Murphy, M.D., both in NIAID’s Laboratory of Infectious Diseases, demonstrated for the first time that these human SARS antibodies, when injected into mice, effectively prevent the virus from multiplying in the respiratory system.

"The antibodies from people who have recovered from SARS may target different parts of the virus than antibodies generated by other animals, such as mice," says Dr. Subbarao. "For this reason, human antibodies--antibodies from recovered patients that may have a proven effectiveness in fighting the disease--are considered most desirable for a possible serotherapy against SARS."

Antibodies are made by special immune system cells called B cells that, to do their job, must first be switched on. In nature, this occurs when the body encounters a new or repeat foreign "invader." In the laboratory, researchers conventionally accomplish this by exposing the B cells to Epstein Barr virus (EBV), a herpes virus that infects B cells, which in turn activates them. Unfortunately, this process is very inefficient, and only one or two B cells out of one hundred are activated this way.

Dr. Lanzavecchia and his research team added a new ingredient to the mix that significantly boosts efficiency. Beginning with B cells from a recovered SARS patient, the researchers added a short stretch of synthetic DNA that mimics DNA found in bacteria and viruses. From 30 to 100 percent of the B cells--in this case called "memory" B cells because they had been exposed to the SARS virus before--were switched back on, enabling them to churn out SARS antibodies at a fast pace. In only a few weeks, the researchers screened hundreds of antibodies and obtained 35 that could neutralize the SARS virus in the laboratory. All the neutralizing antibodies targeted a key SARS protein, the spike protein, found on the virus surface.

Furthermore, when Drs. Subbarao and Murphy injected one of the neutralizing antibodies into mice, they found that these antibodies effectively thwarted the SARS virus from multiplying in the lower respiratory tract, which includes the lungs, and, to a lesser extent, in the upper respiratory tract, which includes the nasal cavity. According to Dr. Subbarao, these results are very promising because replication of SARS in the lungs of humans can result in pneumonia.

A primary benefit of the new activation technique is that it generates a large pool of prospective antibodies from which to choose, so only the most effective SARS fighters can be chosen for use in a possible immune serum. Because viruses can mutate, however, more than one antibody will most likely be needed to achieve the optimal protection or treatment, the researchers contend.

The researchers’ next goal is to find additional antibodies against the SARS virus, focusing on those that attach most readily to the virus, are most potent against the virus, and can attach to more than one site on the spike protein. Before the antibodies might be made available for clinical use, researchers need to test them for their effectiveness in other laboratory animals, such as non-human primates, as well as in human clinical trials.

Jennifer Wenger | EurekAlert!
Further information:
http://www.niaid.nih.gov

More articles from Health and Medicine:

nachricht Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Why we need erasable MRI scans

New technology could allow an MRI contrast agent to 'blink off,' helping doctors diagnose disease

Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

World's smallest optical implantable biodevice

26.04.2018 | Power and Electrical Engineering

Molecular evolution: How the building blocks of life may form in space

26.04.2018 | Life Sciences

First Li-Fi-product with technology from Fraunhofer HHI launched in Japan

26.04.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>